血氨与慢性肝病进展的关系及临床干预

Relationship between blood ammonia and progression of chronic liver disease and its clinical intervention

肝硬化是各种病因引起的肝脏疾病的终末期病变,过去对于肝硬化治疗多以病因管理(抗病毒治疗)和结果管理(出现并发症治疗)为主,但仍存在抗病毒应答率需提高、脂肪肝进程控制不佳及失代偿期肝硬化病情常出现反复等问题。近年来,基于血氨管理控制肝硬化的发展进程的"过程管理"成为新的关注热点,为干预肝硬化进展提供了新的治疗思路。本文就以血氨为靶点监测和干预慢性肝病及肝硬化发展进程的现状作一概述。

Liver cirrhosis is an end-stage disease of liver disease caused by various etiologies. In the past, etiological management(treatment of antiviral) and result management(treatment of complications) were the main treatments for liver cirrhosis, but there were still problems such as increased antiviral response rate, poor control of fatty liver process and often repeated decompensated liver cirrhosis. In recent years, "process management" based on ammonia management to control the development process of cirrhosis has become a new focus of attention, providing a new therapeutic idea for intervening the progression of cirrhosis. This article reviewed the current status of blood ammonia as a target to monitor and intervene in the development of chronic liver disease and liver cirrhosis.